Vulvar pain, itching and burning are common complaints – and often misunderstood. An estimated 10 to 28 percent of all women suffer from vulvodynia in the course of their lives; lichen sclerosus affects around 1.7 percent of the population and is up to 15 times more common than previously diagnosed. Nevertheless, it takes an average of four to seven years for a correct diagnosis to be made. The reason: the overlap between inflammatory dermatoses, functional pain syndromes and oncological precursors requires a systematic clinical assessment, which is often lacking in routine care. The new S3 guideline on lichen sclerosus and a growing body of evidence on the multimodal treatment of vulvodynia offer reliable guidance for the first time.
Autoren
- Tanja Schliebe
Publikation
- GYNÄKOLOGIE PRAXIS
Related Topics
You May Also Like
- Chronic Urticaria: Treatment for Patients Unresponsive to Antihistamines
In addition to anti-IgE antibodies, the guideline recommends anti-IL-4α antibodies and BTK inhibition
- Type 1 Diabetes in Childhood
Early Impairment of Glucagon Counterregulation
- Psychosis in Parkinson's Disease
Be Careful When Choosing Medications
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations
Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis
- Cellular and Systemic Iron Homeostasis
“Steady State” – a delicately balanced equilibrium
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D